No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
165 |
4. Check minimum number of eventsNone |
165 |
5. Include endpointsNone |
165 |
6. Filter based on genotype QC (FinnGen only) |
165 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M48
- Name in latin
- Fractura vertebrae ex fatigatione
Similar endpoints
↥List of similar endpoints to
Fatigue fracture of vertebra
based on the number of shared cases.
Similar with more cases:
- Spondylopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1686 | 892 | 789 |
| Only index persons | 1561 | 823 | 738 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 40.97 | 61.05 | 18.09 |
| Only index persons | 40.52 | 60.94 | 17.75 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 165 | 103 | 62 |
| Unadjusted period prevalence (%) | 0.03 | 0.04 | 0.03 |
| Median age at first event (years) | 62.68 | 62.70 | 62.64 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 143
- Matched controls
- 1430
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M48.4
ICD-10 Finland
Fatigue fracture of vertebra
4503599627370496.0
201.3
142
*
M48.0
ICD-10 Finland
Spinal stenosis
177.0
38.9
39
*
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
42.3
27.0
33
10
M54.5
ICD-10 Finland
Low back pain
7.7
25.8
74
174
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
90.3
21.4
23
*
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
57.1
20.9
24
5
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
22.4
20.1
29
16
M54.4
ICD-10 Finland
Lumbago with sciatica
11.1
19.3
38
45
N03AX16
ATC
pregabalin; oral
7.0
18.8
52
107
M54.9
ICD-10 Finland
Dorsalgia, unspecified
14.9
18.4
31
26
N03AX12
ATC
gabapentin; oral
9.0
17.9
40
59
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
72.4
17.2
19
*
N02AA05
ATC
oxycodone; systemic
6.2
15.1
45
99
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
6.9
15.0
40
76
S32.0
ICD-10 Finland
Fracture of lumbar vertebra
18.5
12.0
18
11
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
130.0
11.6
12
*
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
130.0
11.6
12
*
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
3.7
11.3
64
258
L03
ICPC
Low back symptom/complaint
4.0
10.3
46
150
S22.0
ICD-10 Finland
Fracture of thoracic vertebra
43.4
10.1
12
*
M05BA04
ATC
alendronic acid; oral
5.0
10.1
34
84
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
10.2
9.9
19
21
N02AX02
ATC
tramadol; systemic, rectal
3.3
9.8
67
303
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.3
9.8
67
304
NA3EA
NOMESCO Finland
Lumbar spine X-ray examination with flexion
106.8
9.5
10
*
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
106.8
9.5
10
*
M54.3
ICD-10 Finland
Sciatica
29.5
8.6
11
*
M43.1
ICD-10 Finland
Spondylolisthesis
95.4
8.5
9
*
M25.5
ICD-10 Finland
Pain in joint
3.3
8.3
49
196
N02AJ06
ATC
codeine and paracetamol; systemic
3.1
8.3
58
258
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
35.6
8.2
10
*
M81.9
ICD-10 Finland
Osteoporosis, unspecified
8.2
7.9
17
23
M84.3
ICD-10 Finland
Stress fracture, not elsewhere classified
47.6
7.8
9
*
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
19.7
7.7
11
6
A02BC05
ATC
esomeprazole; systemic
2.8
7.5
66
337
TAC99
NOMESCO Finland
Other blockade for chronic pain
+∞
7.3
7
*
M43.0
ICD-10 Finland
Spondylolysis
+∞
7.3
7
*
M05BX04
ATC
denosumab; parenteral
7.7
7.2
16
23
N06AA09
ATC
amitriptyline; systemic
5.4
7.2
21
44
M54
ICD-10 Finland
Dorsalgia
4.9
7.1
23
54
Z01.8
ICD-10 Finland
Other specified special examinations
3.4
7.1
38
139
L02
ICPC
Back symptom/complaint
5.3
6.5
19
40
NAG62
NOMESCO Finland
Posterior fusion of lumbar spine with fixation, 2-3 vertebraea
+∞
6.3
6
*
ABC56
NOMESCO Finland
Decompression of lumbar spinal canal and nerve roots
+∞
6.3
6
*
NAG40
NOMESCO Finland
Anterior fusion of cervical spine without fixation
+∞
6.3
6
*
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
10.7
6.1
11
11
J01DA01
ATC
[U] cefalexin; systemic
2.4
6.1
83
521
M05BB03
ATC
alendronic acid and colecalciferol; oral
7.8
6.1
13
18
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
4.4
6.0
21
54
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
106
647
2.79
9.08
7.2
6.8
1.2
1.2
mmol/l
1.77
94
560
60
284
2.75
8.39
2.6
2.3
—
—
—
0
0
98
592
2.61
8.31
7.2
6.6
1.2
1.2
mmol/l
1.75
93
540
36
130
3.26
8.13
7.6
6.6
12.3
12.9
kpa
0.27
36
125
88
522
2.47
7.52
2.8
2.4
77.8
75.2
nmol/l
0.36
82
462
31
107
3.34
7.50
4.6
10.3
1.2
1.5
mmol/l
0.85
31
100
126
920
2.56
6.30
5.3
3.8
13.4
12.2
mm/h
0.29
115
834
107
754
2.19
5.41
9.5
9.5
4.0
4.0
e9/l
0.03
94
659
20
65
3.36
5.27
6.9
10.3
93.9
94.9
%
0.37
20
65
125
945
2.33
5.21
9.4
6.3
78.3
86.7
u/l
1.64
120
877
11
23
5.05
5.09
1.2
1.1
—
—
—
0
0
21
72
3.20
5.09
6.4
9.4
1.6
1.2
%
0.54
21
72
21
72
3.20
5.09
6.6
9.4
0.6
0.7
%
0.40
21
72
83
541
2.07
5.03
5.0
4.5
35.2
35.7
g/l
0.30
76
507
44
228
2.27
4.76
1.8
1.6
1141.0
1128.2
nmol/l
0.03
33
173
83
553
2.01
4.62
4.6
3.7
—
—
—
0
0
10
22
4.77
4.36
1.6
1.5
—
—
—
0
0
10
22
4.77
4.36
1.6
1.5
—
—
—
0
0
18
62
3.14
4.32
6.5
9.5
24.1
23.8
mmol/l
0.13
18
57
43
230
2.18
4.27
4.2
3.1
2.5
2.5
mmol/l
0.16
36
204
69
441
1.97
4.24
3.5
3.0
2.3
2.4
mmol/l
1.36
55
387
70
453
1.95
4.12
4.9
3.8
39.0
50.4
ng/l
0.23
48
325
70
463
1.89
3.79
4.4
3.2
—
—
—
0
0
146
1256
2.41
3.36
24.1
13.0
26.5
24.1
mg/l
0.27
123
953
26
125
2.28
3.30
1.9
1.7
—
—
—
0
0
48
295
1.88
3.18
2.4
3.3
321.3
8486.2
umol/l
2.01
37
257
16
62
2.75
3.15
1.3
1.3
—
—
—
0
0
56
363
1.82
3.13
4.2
3.2
0.2
0.4
e6/l
1.21
49
274
6
8
7.73
3.08
1.3
1.6
—
—
—
0
0
33
180
2.04
3.07
1.1
1.2
29.6
38.4
iu/ml
—
5
59
33
185
1.98
2.84
2.2
1.8
—
—
—
0
0
69
488
1.71
2.81
2.4
1.9
93.8
93.2
pmol/l
0.04
42
243
54
361
1.74
2.66
3.2
3.7
1202.6
1447.5
ng/l
0.40
45
313
11
38
3.03
2.63
1.5
1.4
—
—
—
0
0
6
11
5.61
2.56
1.3
1.8
12.7
23.2
ug/l
—
6
11
5
7
7.32
2.56
2.4
2.7
44.9
266.4
ug/l
—
5
7
24
126
2.06
2.46
2.0
1.7
—
—
—
0
0
18
84
2.28
2.45
2.1
1.7
—
—
—
0
0
14
60
2.46
2.29
1.0
1.3
—
—
—
0
0
7
18
4.01
2.28
1.9
1.9
—
—
—
0
0
51
349
1.67
2.27
2.7
2.5
2.9
3.0
mg/l
0.26
45
299
29
171
1.84
2.15
1.3
1.2
1.8
6.2
u/ml
1.07
12
60
72
546
1.57
2.08
2.9
2.8
108.0
108.4
ug/l
0.01
64
500
93
749
1.55
2.05
4.0
3.3
45.3
45.5
u/l
0.01
88
702
9
33
2.82
1.96
1.0
1.2
—
—
—
0
0
5
11
4.65
1.95
3.4
3.8
—
—
—
0
0
97
796
1.53
1.91
3.2
3.0
—
—
—
0
0
5
12
4.26
1.83
2.8
4.1
2.4
4.6
nmol/l
—
5
12
9
35
2.66
1.83
1.0
1.1
—
—
—
0
0
19
104
1.93
1.76
2.2
2.6
4.4
5.8
ug/l
0.69
13
91
15
75
2.10
1.76
1.1
1.3
372.4
170.0
iu/ml
—
5
35
11
48
2.38
1.74
2.5
2.0
—
—
—
0
0
5
13
3.93
1.72
1.8
1.9
—
—
—
0
0
5
13
3.93
1.72
1.8
1.9
—
—
—
0
0
5
13
3.93
1.72
1.8
1.9
—
—
—
0
0
5
13
3.93
1.72
1.8
1.9
—
—
—
0
0
5
14
3.65
1.62
1.8
1.9
—
—
—
0
0
5
14
3.65
1.62
1.2
1.2
—
—
—
0
0
5
14
3.65
1.62
1.8
1.9
—
—
—
0
0
111
957
1.49
1.58
4.9
3.9
14.7
14.9
pmol/l
0.21
98
859
21
126
1.76
1.49
4.2
4.4
31.5
33.1
%
0.31
16
75
10
46
2.25
1.43
1.5
1.8
—
—
—
0
0
32
219
1.57
1.40
3.6
3.0
0.5
1.2
e6/l
1.59
20
130
5
17
3.00
1.37
1.2
1.5
—
—
—
0
0
14
78
1.87
1.25
6.2
5.6
24.8
25.2
mmol/l
0.18
14
78
144
1337
1.61
1.21
13.2
9.5
22.2
24.3
u/l
1.33
136
1282
129
1173
1.46
1.18
5.9
4.5
2.0
2.0
mu/l
0.02
120
1059
8
39
2.10
1.17
1.8
1.3
—
—
—
0
0
5
20
2.54
1.16
1.6
1.7
—
—
—
0
0
5
20
2.54
1.16
1.0
1.1
—
—
—
0
0
31
221
1.50
1.14
3.7
3.0
2.1
3.1
e6/l
0.40
19
135
17
105
1.69
1.11
5.5
5.1
5.2
5.2
kpa
0.07
17
97
13
74
1.82
1.10
1.8
3.0
67.6
59.2
ml/min/173m2
—
7
32
19
123
1.62
1.05
2.7
9.8
24.3
24.8
mmol/l
0.25
19
123
9
159
0.54
1.05
1.9
1.4
—
—
—
0
0
42
324
1.40
1.03
1.5
1.6
1.5
1.0
u/ml
0.32
11
64
0
29
0.00
0.98
0.0
1.1
—
110.2
—
0
5
69
582
1.32
0.95
4.7
3.8
0.0
0.0
estimate
—
8
112
6
27
2.27
0.94
1.2
1.2
55.3
39.1
nmol/l
—
6
27
8
43
1.90
0.88
1.4
1.1
—
—
—
0
0
8
44
1.86
0.87
1.6
2.6
28.0
14.6
iu/l
—
8
32
126
1166
1.34
0.83
26.5
15.5
38.9
39.0
%
0.07
88
868
0
25
0.00
0.79
0.0
1.3
—
3.3
—
0
13
69
595
1.27
0.78
6.1
5.4
0.0
0.0
estimate
—
9
115
69
600
1.26
0.71
4.7
3.8
0.0
0.0
estimate
—
8
113
5
27
1.88
0.69
1.6
1.4
—
—
—
0
0
18
129
1.44
0.67
12.0
6.4
—
—
—
0
0
5
28
1.81
0.66
1.6
2.3
—
—
—
0
0
31
247
1.31
0.63
1.5
1.8
523.6
437.7
pmol/l
0.40
20
204
32
257
1.30
0.61
1.8
1.7
—
—
—
0
0
17
125
1.40
0.56
2.9
6.9
9.4
8.5
mmol/l
0.20
17
115
39
326
1.26
0.55
4.5
4.8
2.6
3.2
ug/l
0.17
34
292
27
333
0.77
0.55
1.5
1.5
1.2
1.3
mmol/l
0.25
18
276
6
40
1.52
0.52
3.5
2.0
—
—
—
0
0
9
65
1.41
0.51
2.7
1.7
—
—
—
0
0
8
118
0.66
0.47
3.3
2.1
—
—
—
0
0
5
82
0.60
0.47
1.0
1.0
—
—
—
0
0
31
260
1.24
0.43
2.5
4.1
22.2
21.4
%
0.07
15
130
16
123
1.33
0.42
4.9
2.9
—
—
—
0
0
0
15
0.00
0.41
0.0
1.7
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
126
1206
1.19
0.38
4.5
4.8
2.5
2.6
mmol/l
0.65
113
1104
6
47
1.29
0.32
3.3
2.1
—
—
—
0
0
5
74
0.67
0.26
1.8
1.8
—
—
—
0
0
116
1121
1.12
0.23
3.8
3.9
1.2
1.2
mmol/l
0.03
106
1024
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
9
106
0.84
0.13
2.7
2.0
—
—
—
0
0
120
1183
1.05
0.07
4.6
4.4
5.8
6.0
mmol/l
1.55
107
1074
9
88
1.02
0.07
1.2
1.6
—
—
—
0
0
9
100
0.89
0.06
4.4
3.5
1.2
1.2
mmol/l
—
9
84
113
1114
1.05
0.06
5.8
6.1
39.3
40.6
mmol/mol
0.93
105
1033
118
1168
1.04
0.04
4.3
4.2
1.5
1.5
mmol/l
0.32
107
1068
32
312
1.03
0.02
6.7
3.8
0.0
0.0
estimate
—
8
114
117
1177
0.98
0.01
4.2
4.3
4.4
4.5
mmol/l
0.61
105
1084
112
1113
1.02
0.01
23.1
12.6
80.4
78.5
ml/min/173m2
0.40
98
892
12
117
1.03
0.00
1.9
2.2
1.7
1.5
%
0.41
12
105
46
465
0.99
0.00
6.0
4.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
4.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
203.0
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
161.6
—
0
9
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
4.0
—
140.4
—
0
9
Mortality – FinRegistry
↥Association
Association between endpoint M13_FATIGFRACT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_FATIGFRACT | 1.518 [1.15, 2.0] | 0.003 |
| Birth year | 0.996 [0.99, 1.0] | 0.403 |
During the follow-up period (1.1.1998 — 31.12.2019), 179 out of 579 females with M13_FATIGFRACT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_FATIGFRACT | 1.865 [1.31, 2.66] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 109 out of 387 males with M13_FATIGFRACT died.
Mortality risk
Mortality risk for people of age
years, who have M13_FATIGFRACT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.183% | 0.329% |
| 5 | 0.973% | 1.964% |
| 10 | 2.401% | 4.885% |
| 15 | 4.479% | 8.956% |
| 20 | 7.785% | 15.13% |
Relationships between endpoints
↥Index endpoint: M13_FATIGFRACT – Fatigue fracture of vertebra
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data